TheraRadar
Data updated: May 26, 2026

PHEBURANE (sodium phenylbutyrate)

Rare Disease Approved 2022-06-17

PHEBURANE is indicated for the treatment of Urea Cycle Disorder.

Source: FDA Label • MEDUNIK

How PHEBURANE Works

Sodium phenylbutyrate is a prodrug that is metabolized to phenylacetate. Phenylacetate conjugates with glutamine via acetylation to form phenylacetylglutamine, which is then excreted by the kidneys. This process provides an alternative pathway for waste nitrogen excretion, bypassing the deficient enzymes of the urea cycle.

1
Indication
--
Phase 3 Trials
3
Years on Market

Details

Status
Prescription
First Approved
2022-06-17
Routes
ORAL
Dosage Forms
PELLETS

Companies

Active Ingredient: SODIUM PHENYLBUTYRATE

PHEBURANE Approval History

2023
2024
2025
2026
Original
New Indication
New Form
Label Update
1 FDA actions from 2022 to 2022
Jun 2022 ORIGINAL
Update · Type 5 - New Formulation or New Manufacturer

What PHEBURANE Treats

1 indications

PHEBURANE is approved for 1 conditions since its original approval in 2022. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Urea Cycle Disorder
Source: FDA Label

PHEBURANE Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 2 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to PHEBURANE

3 of 4

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

OLPRUVA
SODIUM PHENYLBUTYRATE
1 shared
ACER
Shared indications:
Urea Cycle Disorder
RAVICTI
GLYCEROL PHENYLBUTYRATE
1 shared
HORIZON THERAP US
Shared indications:
Urea Cycle Disorder
SODIUM PHENYLACETATE AND SODIUM BENZOATE
SODIUM BENZOATE
1 shared
MAIA PHARMS INC
Shared indications:
Urea Cycle Disorder
📋

Clinical Trial Registry

9 trials
Trial Sponsor ID Phase Status Title
NCT06069375 STUDY23060034 Ph 2 suspended Study of Sodium Phenylbutyrate (ACER-001) for the Treatment of Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)
NCT07125066 STUDY25060137 Ph 1 enrolling by invitation An Individual Patient, Open Label Study to Use ACER-001 to Treat Combined D,L-2 Hydroxyglutaric Aciduria (C-2HGA)
NCT06773026 STUDY24100064 Ph 2 recruiting Study of Sodium Phenylbutyrate (ACER-001) for the Treatment of Pediatric and Adults Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)
NCT05349435 PBI-4050-CT-9-21 Ph 1 terminated A Healthy Volunteer Study to Compare Fezagepras (PBI-4050) With Sodium Phenylbutyrate
NCT03734263 TIGEM2-PDH TIGEM2-PDH Ph 2 completed Use of Phenylbutyrate Therapy for Patients With Pyruvate Dehydrogenase Complex Deficiency.
NCT00345605 results posted RDCRN 5102 U54HD061221 Ph 2 completed Arginine and Buphenyl in Patients With Argininosuccinic Aciduria (ASA), a Urea Cycle Disorder
NCT01096095 CONEP CAAE 0527.0.001.000-07 Ph 2 withdrawn Pilot Study of Safety and Efficacy of Sodium Phenylbutyrate in Spinocerebellar Ataxia Type 3
NCT00439218 NPTUNE 02 results posted N01NS42361_NPTUNE02 HHSN265200423611C, N01NS42361 Ph 1, Ph 2 terminated Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Type I
NCT00439569 NPTUNE01 results posted N01NS42361_NPTUNE01 HHSN265200423611C, N01NS42361 Ph 1, Ph 2 terminated Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Types II or III
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

PHEBURANE FDA Label Details

Indications & Usage

FDA Label (PDF)

PHEBURANE is indicated for the treatment of Urea Cycle Disorder.

Track PHEBURANE with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.